Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18625829 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | April 2024 | August 2024 | Abandon | 4 | 0 | 1 | Yes | No |
| 17719821 | COMPOSITIONS AND METHODS FOR MODULATING PNPLA3 EXPRESSION | April 2022 | April 2024 | Allow | 24 | 1 | 1 | No | No |
| 17717174 | COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK) | April 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17702978 | RNA-Editing Enzyme-Recruiting Oligonucleotides and Uses Thereof | March 2022 | November 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17554026 | ANTISENSE OLIGONUCLEOTIDE AND DOUBLE STRANDED RNAS FOR CONTROL OF HEMIPTERAN AND LEPIDOPTERAN PESTS | December 2021 | July 2023 | Allow | 19 | 2 | 0 | Yes | No |
| 17552804 | Antisense Oligonucleotide for Targeting Progranulin | December 2021 | June 2024 | Allow | 30 | 3 | 1 | No | No |
| 17643807 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | December 2021 | August 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17491064 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING, TREATING AND DIAGNOSING A NEURODEGENERATIVE DISEASE | September 2021 | August 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17401200 | KLF11 siRNA For Treatment Of Diabetes And Obesity | August 2021 | February 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17362567 | COMPOUNDS AND METHODS FOR MODULATING PLP1 | June 2021 | March 2023 | Allow | 21 | 1 | 0 | No | No |
| 17336233 | SYSTEM AND METHOD FOR COLD ATMOSPHERIC PLASMA BASED T CELL THERAPY | June 2021 | October 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17324690 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | May 2021 | March 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17213294 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | March 2021 | September 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17253484 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | March 2021 | February 2023 | Allow | 26 | 1 | 0 | No | No |
| 17153276 | ENGINEERED INCOHERENT FEED FORWARD LOOP AND USES THEREOF | January 2021 | September 2024 | Abandon | 44 | 3 | 1 | No | No |
| 17259366 | Methods for Oral Delivery of Oligonucleotides | January 2021 | July 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17145457 | TREATING CANCER WITH VIRAL NUCLEIC ACID | January 2021 | April 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17139161 | OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION | December 2020 | April 2023 | Allow | 27 | 2 | 0 | No | No |
| 17256136 | METHODS FOR TREATING OR PREVENTING CONFORMATION DISEASES AND METHODS FOR DRUG SCREENING | December 2020 | August 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17127099 | ENHANCED OLIGONUCLEOTIDES FOR INHIBITING SCN9A EXPRESSION | December 2020 | June 2024 | Abandon | 42 | 3 | 1 | No | No |
| 17253102 | IL-1 BETA TARGETING SPHERICAL NUCLEIC ACIDS | December 2020 | June 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17056949 | DELIVERY OF DNA | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17097574 | RNAI TARGET GENE THAT IS HIGHLY LETHAL TO APHIDS AND USE THEREOF | November 2020 | March 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17048163 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 15733580 | METHOD FOR CONTROLLING PEST INFESTATIONS | September 2020 | December 2023 | Allow | 39 | 1 | 0 | No | No |
| 16869126 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | May 2020 | June 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16760593 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | April 2020 | August 2023 | Allow | 40 | 2 | 1 | No | No |
| 16759362 | COMPOSITION OF DRUG TARGETS AND METHOD OF USING THEREOF | April 2020 | February 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 16634078 | Method of Preparing Oligonucleotide Compounds | January 2020 | July 2023 | Abandon | 42 | 0 | 1 | No | No |
| 16624977 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | December 2019 | May 2024 | Abandon | 53 | 2 | 1 | No | Yes |
| 16659368 | ANTISENSE COMPOUNDS | October 2019 | February 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16307695 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATION OF LONG NONCODING RNAS | December 2018 | February 2024 | Abandon | 60 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VYAS, KEYUR ANILKUMAR.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VYAS, KEYUR ANILKUMAR works in Art Unit 1635 and has examined 31 patent applications in our dataset. With an allowance rate of 32.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner VYAS, KEYUR ANILKUMAR's allowance rate of 32.3% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VYAS, KEYUR ANILKUMAR receive 1.03 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by VYAS, KEYUR ANILKUMAR is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +75.0% benefit to allowance rate for applications examined by VYAS, KEYUR ANILKUMAR. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 125.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.